Citizens lowered the firm’s price target on Waystar (WAY) to $34 from $48 and keeps an Outperform rating on the shares. Management’s consistent messaging around the increasingly AI-enabled nature of its solutions, the value of its unique, scaled and proprietary data set, the network effects of joining the platform, multi-sided connectivity, and the comprehensive nature of its solution suite — while operating within the highly regulated and security-sensitive healthcare ecosystem — should help to assuage sector-related AI concerns over time, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WAY:
- Waystar price target lowered to $36 from $42 at Barclays
- AI Risks Loom Over Waystar Holding Corp.: Analyst Flags Legal, Operational, and Competitive Threats
- Waystar: AI-Enabled Growth, Durable Data Moat, and Cautiously Set 2026 Outlook Support Buy Rating
- Waystar Holding Corp. Signals Confident, Profitable Growth
- Waystar: AI-Driven Growth and Solid Execution Underpin Buy Rating Despite Sector Valuation Pressure